A federal class-action lawsuit alleges Blue Owl Capital, a major player in the $1.7 trillion private credit market, restricted investor withdrawals amid mounting redemptions, testing Wall Street's promise of 'democratized' alternative investments for Main Street.
As Ingredion prepares to release its fourth-quarter results, investors are weighing whether the company can stabilize after a disappointing prior quarter. The broader staples sector's recent strength offers a cautiously optimistic backdrop.
A significant purchase of the VictoryShares USAA Core Short-Term Bond ETF (USTB) by wealth manager Merit Financial Group highlights institutional interest in short-duration, income-focused strategies amid market uncertainty.
Samsung Electronics has launched a special edition Galaxy Z Flip7 for the 2026 Winter Olympics, packed with AI-powered translation and athlete-centric features, while also previewing new on-screen privacy controls designed to thwart 'shoulder surfing'. These dual announcements underscore the tech giant's push to blend high-profile partnerships with user-centric innovation as it seeks to differentiate in a competitive market.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
While Insas Berhad's (KLSE:INSAS) share price has underperformed the broader market over three years, its total shareholder return tells a different story. A closer look reveals a disconnect between stock performance and underlying business fundamentals, prompting investor scrutiny.
Micron Technology, a key player in memory chips, is poised for explosive earnings growth fueled by insatiable AI demand. Yet, its cyclical nature and commoditized market pose significant long-term risks for investors.
Asset managers ramped up bearish bets against the U.S. dollar to their highest level in months, only to be blindsided by a sudden rally fueled by speculation that former Fed Governor Kevin Warsh is President Trump's pick to lead the central bank.
Nvidia is set to make a landmark investment in OpenAI's latest funding round, CEO Jensen Huang confirmed, signaling a deepening alliance between the AI hardware giant and the leading AI research lab. However, reports of internal skepticism at Nvidia introduce uncertainty into the final terms and timing of the deal.
Crude futures retreated sharply on Monday after weekend comments from U.S. President Donald Trump suggested diplomatic engagement with Iran, easing fears of a military confrontation that had recently buoyed markets.
Shares of materials and labeling giant Avery Dennison (NYSE: AVY) have shown resilience amid broader market swings, reigniting debate over its intrinsic value. With a significant gap between its current price and analyst targets, investors are weighing its growth in digital identification technologies against persistent sector headwinds.
Goldcom's (GOLD) shares have soared nearly 90% in the past year, leaving investors to grapple with a critical question: has the market already priced in all the good news, or is there still room to run? A deep dive into the valuation metrics reveals a stark contradiction.
Vital Farms (VITL) is drawing renewed investor attention following a series of earnings estimate upgrades and consistent beats. Despite a recent pullback, analysts see significant upside, citing strong brand positioning and operational scale. However, underlying challenges in retail volumes and cash flow present a more complex picture for the pasture-raised egg producer.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
The Malaysian electronics manufacturing services provider is showing compelling financial momentum, with its return on capital employed significantly outpacing industry averages and signaling potential for sustained growth.
With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.
As Apple's stock experiences recent volatility, investors are grappling with a critical question: does its current price reflect its long-term potential? A deep dive into valuation models reveals a complex picture, with traditional metrics painting conflicting signals about the iPhone maker's true worth.
First American Financial Corp. announces the retirement of director Martha Wyrsch while reaffirming its quarterly dividend, signaling stability in shareholder returns during a period of governance change. The company's stock performance and capital allocation strategy remain in focus for investors.
The iconic outdoor retailer Eddie Bauer is preparing to file for Chapter 11 bankruptcy, a move that will close its entire fleet of roughly 200 physical stores across the U.S. and Canada. While its e-commerce and wholesale operations will live on, the decision marks a dramatic retreat from the mall landscape it helped define for decades.
